Dr. Manfred Ziegler Joins Flora Growth Corp. as Managing Director, Bolstering German Business with Unmatched Expertise
Flora Growth Corp. (NASDAQ: FLGC) has appointed Dr. Manfred Ziegler as Managing Director to bolster its German business. Dr. Ziegler, a renowned figure in the pharmaceutical industry, brings decades of expertise, including his leadership as Managing Director of CC Pharma and his role in its sale to Tilray. His appointment is expected to accelerate Flora's ambition to become a leading cannabis company in Germany.
Dr. Ziegler's extensive experience includes transforming CC Pharma into one of Europe's leading pharmaceutical distributors. His strategic leadership and proven ability to drive growth in complex markets will be instrumental as Flora expands its operations in Germany and Europe's cannabis sector. In his new role, Dr. Ziegler will focus on international distribution strategies, regulatory compliance, and market expansion, with a key objective to spearhead the launch of Flora's parallel import business in Germany.
Flora Growth Corp. (NASDAQ: FLGC) ha nominato Dr. Manfred Ziegler come Amministratore Delegato per rafforzare il suo business in Germania. Il Dr. Ziegler, una figura rinomata nell'industria farmaceutica, porta con sé decenni di esperienza, inclusa la sua leadership come Amministratore Delegato di CC Pharma e il suo ruolo nella vendita della società a Tilray. Ci si aspetta che la sua nomina acceleri l'ambizione di Flora di diventare una delle principali aziende di cannabis in Germania.
La vasta esperienza del Dr. Ziegler include la trasformazione di CC Pharma in uno dei principali distributori farmaceutici in Europa. La sua leadership strategica e la comprovata capacità di stimolare la crescita in mercati complessi saranno determinanti mentre Flora espande le sue operazioni in Germania e nel settore della cannabis in Europa. Nel suo nuovo ruolo, il Dr. Ziegler si concentrerà sulle strategie di distribuzione internazionale, sul rispetto delle normative e sull'espansione del mercato, con l'obiettivo chiave di guidare il lancio del business di importazione parallela di Flora in Germania.
Flora Growth Corp. (NASDAQ: FLGC) ha nombrado al Dr. Manfred Ziegler como Director General para fortalecer su negocio en Alemania. El Dr. Ziegler, una figura reconocida en la industria farmacéutica, aporta décadas de experiencia, incluyendo su liderazgo como Director General de CC Pharma y su papel en la venta de la empresa a Tilray. Se espera que su nombramiento acelere la ambición de Flora de convertirse en una empresa líder en cannabis en Alemania.
La amplia experiencia del Dr. Ziegler incluye la transformación de CC Pharma en uno de los principales distribuidores farmacéuticos de Europa. Su liderazgo estratégico y su capacidad comprobada para impulsar el crecimiento en mercados complejos serán fundamentales mientras Flora expande sus operaciones en Alemania y en el sector del cannabis europeo. En su nuevo rol, el Dr. Ziegler se centrará en estrategias de distribución internacional, cumplimiento normativo y expansión del mercado, con el objetivo clave de liderar el lanzamiento del negocio de importación paralela de Flora en Alemania.
플로라 성장 코퍼레이션(상장: FLGC)은 독일 사업을 강화하기 위해 맨프레드 지글러 박사를 관리 이사로 임명했습니다. 지글러 박사는 제약 산업에서 저명한 인물로, CC Pharma의 관리 이사로서의 리더십과 Tilray에 대한 판매 작업을 포함한 수십 년의 전문성을 지니고 있습니다. 그의 임명이 플로라가 독일에서 주요한 대마초 회사로 자리 잡으려는 야망을 가속화할 것으로 기대됩니다.
지글러 박사의 방대한 경험에는 CC Pharma을 유럽의 주요 제약 유통업체 중 하나로 변화시키는 것이 포함됩니다. 그의 전략적 리더십과 복잡한 시장에서 성장을 이끌 수 있는 입증된 능력은 플로라가 독일과 유럽의 대마초 부문에서 사업을 확장하는 데 중요한 역할을 할 것입니다. 새로운 역할에서 지글러 박사는 국제 유통 전략, 규제 준수 및 시장 확장에 집중하며, 플로라의 병행 수입 비즈니스가 독일에서 시작되는 것을 주도하는 것이 주요 목표입니다.
Flora Growth Corp. (NASDAQ: FLGC) a nommé Dr. Manfred Ziegler en tant que Directeur Général pour renforcer son activité en Allemagne. Le Dr. Ziegler, une figure renommée dans l'industrie pharmaceutique, apporte des décennies d'expertise, y compris son leadership en tant que Directeur Général de CC Pharma et son rôle dans la vente de l'entreprise à Tilray. Sa nomination devrait accélérer l'ambition de Flora de devenir une société de cannabis leader en Allemagne.
La vaste expérience du Dr. Ziegler inclut la transformation de CC Pharma en l'un des principaux distributeurs pharmaceutiques en Europe. Son leadership stratégique et sa capacité prouvée à stimuler la croissance sur des marchés complexes seront essentiels alors que Flora étend ses opérations en Allemagne et dans le secteur du cannabis en Europe. Dans son nouveau rôle, le Dr. Ziegler se concentrera sur les stratégies de distribution internationale, la conformité réglementaire et l'expansion du marché, avec l'objectif clé de diriger le lancement de l'activité d'importation parallèle de Flora en Allemagne.
Flora Growth Corp. (NASDAQ: FLGC) hat Dr. Manfred Ziegler als Geschäftsführer ernannt, um sein Geschäft in Deutschland zu stärken. Dr. Ziegler, eine angesehene Persönlichkeit in der Pharmaindustrie, bringt Jahrzehnte an Expertise mit, einschließlich seiner position als Geschäftsführer von CC Pharma und seiner Rolle beim Verkauf des Unternehmens an Tilray. Seiner Ernennung wird voraussichtlich Flora's Bestrebungen beschleunigen, ein führendes Cannabis-Unternehmen in Deutschland zu werden.
Die umfangreiche Erfahrung von Dr. Ziegler umfasst die Transformation von CC Pharma in einen der führenden pharmazeutischen Distributoren Europas. Sein strategisches Leadership und seine nachgewiesene Fähigkeit, in komplexen Märkten Wachstum zu fördern, werden entscheidend sein, während Flora seine Geschäfte in Deutschland und im europäischen Cannabissektor ausbaut. In seiner neuen Rolle wird Dr. Ziegler sich auf internationale Vertriebsstrategien, die Einhaltung von Vorschriften und die Markterweiterung konzentrieren, mit dem Hauptziel, die Einführung von Floras Parallelimportgeschäft in Deutschland zu leiten.
- Appointment of Dr. Manfred Ziegler, a renowned industry expert, as Managing Director
- Potential acceleration of Flora's growth and market share in Germany's cannabis sector
- Dr. Ziegler's expertise in pharmaceutical distribution and strategic transactions
- Planned launch of parallel import business in Germany to provide competitive pricing
- None.
Fort Lauderdale, Florida--(Newsfile Corp. - October 10, 2024) - Flora Growth Corp. (NASDAQ: FLGC) (FSE: 7301) ("Flora" or the "Company") is pleased to announce the appointment of Dr. Manfred Ziegler as a Managing Director. Dr. Ziegler, a renowned figure in the pharmaceutical industry, brings decades of expertise, notably his leadership as Managing Director of CC Pharma and his pivotal role in the sale of CC Pharma to Tilray, one of the world's leading cannabis companies.
With the appointment of Dr. Ziegler, Flora Growth is poised to accelerate its ambition to become one of the leading cannabis companies in Germany. His strategic leadership and proven ability to drive growth in complex markets will be instrumental as Flora expands its operations in Germany, targeting increased market share and a stronger foothold in Europe's rapidly evolving cannabis sector.
Dr. Ziegler's tenure at CC Pharma marked a period of growth and strategic innovation. As Managing Director, he transformed the company into one of Europe's leading pharmaceutical distributors, with a robust portfolio and a significance presence in the European market. His leadership was instrument in the successful acquisition of CC Pharma by Tilray.
The sale of CC Pharma to Tilray was a significant transaction in the cannabis and pharmaceutical sectors. This acquisition positioned Tilray as a key player in the European medical cannabis market, leveraging CC Pharma's established distribution network to expand its reach in the rapidly growing sector.
Dr. Manfred Ziegler is a seasoned executive with over 30 years of experience in the pharmaceutical and healthcare sectors, recognized for his expertise in corporate restructuring and business transformation. Prior to his tenure at CC Pharma, Dr. Ziegler held leadership roles at several prominent companies, where he managed complex international operations and contributed to substantial revenue growth. His track record of strategic realignment and operational efficiency has made him a respected leader in the industry.
"Dr. Ziegler is a legend and a complete gentleman. We are thrilled he is coming in to lead all initiatives in Germany, which will snowball to the rest of Europe. We could not have found anyone more qualified for this role. We both share the same vision of becoming a leader in Germany and creating a long-lasting business in Europe," said Clifford Starke, Chief Executive Officer.
In his role as Managing Director, Dr. Ziegler will work closely with Flora's executive team, providing insights and guidance on international distribution strategies, regulatory compliance, and market expansion. His understanding of the German market, combined with his experience in overseeing large-scale transactions, will be critical as Flora accelerates its growth plans and pursues opportunities in Europe.
One of Dr. Ziegler's key objectives will be to spearhead the launch of the Company's parallel import business in Germany. Parallel importing involves purchasing pharmaceutical products from other EU countries where prices are lower, and then importing them into Germany to sell at competitive rates. This practice is highly regulated but provides an opportunity to reduce costs for consumers and increase Flora's market presence. Dr. Ziegler's vast experience in the pharmaceutical sector, particularly in navigating regulatory complexities and optimizing supply chains, will be critical in establishing Flora as a leader in this space, helping the company provide affordable, high-quality products to the German market.
"I am excited to join Flora at such a pivotal time in the Company's journey," said Dr. Ziegler. "Flora's track record of innovation and quality, along with its business ambitions, align well with my experience and vision for the future of the pharmaceutical industry. I look forward to contributing to the Company's continued success and helping to shape its strategic direction."
About Flora Growth Corp.
Flora Growth Corp.'s mission is to become the leading NASDAQ small-cap international cannabis company. Flora is a cannabis-focused consumer-packaged goods leader and pharmaceutical distributor serving all 50 states and 28 countries with 20,000+ points of distribution around the world. For more information on Flora, visit www.floragrowth.com.
https://www.phatebo.de/home-en
https://www.australianvaporizers.com.au/
Investor Relations:
Investor Relations ir@floragrowth.com
Clifford Starke Clifford.Starke@floragrowth.com
Media:
Cautionary Statement Concerning Forward-Looking Statements
This press release contains "forward-looking statements," as defined by U.S. federal securities laws. Forward-looking statements reflect Flora's current expectations and projections about future events at the time, and thus involve uncertainty and risk. The words "believe," "expect," "anticipate," "will," "could," "would," "should," "may," "plan," "estimate," "intend," "predict," "potential," "continue," and the negatives of these words and other similar expressions generally identify forward-looking statements. These forward-looking statements include, but are not limited to, statements about: Flora becoming a leader in Germany and creating a long-lasting business in Europe or at all, expanding our footprint in Europe and deliver strategic solutions to our operations, Flora accelerate its ambition to become one of the leading cannabis companies in Germany, Dr. Ziegler driving growth in complex markets as Flora expands its operations in Germany, Flora expanding its operations in Germany, targeting increased market share and a stronger foothold in Europe's rapidly evolving cannabis sector, Flora launching the parallel import business, and Flora accelerating its growth plans and pursues opportunities in Europe. Such forward-looking statements are subject to various and risks and uncertainties, including those described under section entitled "Risk Factors" in Flora's Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (the "SEC") on March 28, 2024, as such factors may be updated from time to time in Flora's periodic filings with the SEC, which are accessible on the SEC's website at www.sec.gov/edgar. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in Flora's filings with the SEC. While forward-looking statements reflect Flora's good faith beliefs, they are not guarantees of future performance. Flora disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events or other changes after the date of this press release, except as required by applicable law. You should not place undue reliance on any forward-looking statements, which are based on information currently available to Flora (or to third parties making the forward-looking statements).
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/226168
FAQ
Who is Dr. Manfred Ziegler and what is his new role at Flora Growth Corp (FLGC)?
What is Dr. Ziegler's background and how might it benefit Flora Growth Corp (FLGC)?
What are Dr. Ziegler's main objectives in his new role at Flora Growth Corp (FLGC)?
How does Flora Growth Corp (FLGC) plan to enter the German market?
